Journal: Neoplasia (New York, N.Y.)

Article Title: Synergistic Signaling of KRAS and Thyroid Hormone Receptor β Mutants Promotes Undifferentiated Thyroid Cancer through MYC Up-Regulation 1 2

doi: 10.1016/j.neo.2014.08.003

Figure Lengend Snippet: Poor survival of Thrb PV/PV Kras G12D mice. (A-I) Protein levels of ERK and AKT in the thyroids of WT, Kras G12D , Thrb PV/PV , and Thrb PV/PV Kras G12D mice. Western blot analyses for p-ERK (a), total ERK (b), phosphorylated AKT (c), total AKT (d), and GAPDH (e), as loading control, were carried out as described in the Materials and Methods section. Representative results from two mice are shown and the genotypes are marked. (A-II) The band intensities were quantified by image analysis and p-ERK/total ERK ratios were determined using GAPDH as loading control. (A-III) The band intensities were quantified by image analysis and p-AKT/total AKT ratios were determined using GAPDH as loading control. (B) The Kaplan-Meier survival curves for WT, Kras G12D , Thrb PV/PV , and Thrb PV/PV Kras G12D mice up to 10.5 months of age. The Kaplan-Meier cumulative survival analysis was performed using GraphPad Prism version 5.0 for Mac OS X. Survival rates of Thrb PV/PV Kras G12D ( n = 42) and mice with other genotypes were significantly different ( P < .01). (C) Thyroid glands of the mice with four genotypes ( n = 9-22) were dissected and compared in the same age groups. The difference in the thyroid weight between Thrb PV/PV Kras G12D mice and the mice with other genotypes was significant at 2 to 10.4 months ( P < .01), as determined by ANOVA.

Article Snippet: The Kaplan-Meier cumulative survival analysis was performed using GraphPad Prism version 5.0 for Mac OS X.

Techniques: Western Blot

Journal: Cancer immunology, immunotherapy : CII

Article Title: Ex vivo conditioning with IL-12 protects tumor infiltrating CD8 + T cells from negative regulation by local IFN-γ

doi: 10.1007/s00262-018-2280-3

Figure Lengend Snippet: (a) Circulating levels of adoptively transferred PmelAg or IFNγR−/− PmelAg ex vivo expanded in the presence of antigen plus or minus IL-12 at days 5 and 13 after infusion into wild type mice bearing B16 melanoma tumors. Data is presented as the average percent of CD8+/Thy1.1+ cells of total lymphocytes ± SD. (n=4-5) (b) Tumor progression and (c) overall survival of mice treated with CTX alone or with either PmelAg, PmelAg+12 or IFNγR−/− PmelAg cells. Two tailed student t-test was used, *p<0.05, **p<0.005, and *** p<0.0001. Cumulative survival was calculated using a Kaplan- Meier curve using Graphpad Prism (n=5). Data shown is representative of at least three independent experiments.

Article Snippet: Cumulative survival was calculated using a Kaplan- Meier curve using Prism (GraphPad, La Jolla, CA).

Techniques: Ex Vivo, Two Tailed Test